Literature DB >> 19602213

Expected value of perfect information: an empirical example of reducing decision uncertainty by conducting additional research.

Jan B Oostenbrink1, Maiwenn J Al, Mark Oppe, Maureen P M H Rutten-van Mölken.   

Abstract

OBJECTIVE: Value of information (VOI) analysis informs decision-makers about the expected value of conducting more research to support a decision. This expected value of (partial) perfect information (EV(P)PI) can be estimated by simultaneously eliminating uncertainty on all (or some) parameters involved in model-based decision-making. This study aimed to calculate the EVPPI, before and after collecting additional information on the parameter of a probabilistic Markov model with the highest EVPPI.
METHODS: The model assessed the 5-year costs per quality-adjusted life year (QALY) of three bronchodilators in chronic obstructive pulmonary disease (COPD). It had identified tiotropium as the bronchodilator with the highest expected net benefit. Total EVPI was estimated plus the EVPPIs for four groups of parameters: 1) transition probabilities between COPD severity stages; 2) exacerbation probabilities; 3) utility weights; and 4) costs. Partial EVPI analyses were performed using one-level and two-level sampling algorithms.
RESULTS: Before additional research, the total EVPI was Euro 1985 per patient at a threshold value of Euro 20,000 per QALY. EVPPIs were Euro 1081 for utilities, Euro 724 for transition probabilities, and relatively small for exacerbation probabilities and costs. A large study was performed to obtain more precise EQ-5D utilities by COPD severity stages. After using posterior utilities, the EVPPI for utilities decreased to almost zero. The total EVPI for the updated model was reduced to Euro 1037. With an EVPPI of Euro 856, transition probabilities were now the single most important parameter contributing to the EVPI.
CONCLUSIONS: This VOI analysis clearly identified parameters for which additional research is most worthwhile. After conducting additional research on the most important parameter, i.e., the utilities, total EVPI was substantially reduced.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19602213     DOI: 10.1111/j.1524-4733.2008.00389.x

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  20 in total

1.  Value-of-information analysis to reduce decision uncertainty associated with the choice of thromboprophylaxis after total hip replacement in the Irish healthcare setting.

Authors:  Laura McCullagh; Cathal Walsh; Michael Barry
Journal:  Pharmacoeconomics       Date:  2012-10-01       Impact factor: 4.981

2.  "Time Traveling Is Just Too Dangerous" but Some Methods Are Worth Revisiting: The Advantages of Expected Loss Curves Over Cost-Effectiveness Acceptability Curves and Frontier.

Authors:  Fernando Alarid-Escudero; Eva A Enns; Karen M Kuntz; Tzeyu L Michaud; Hawre Jalal
Journal:  Value Health       Date:  2019-05       Impact factor: 5.725

Review 3.  A systematic and critical review of the evolving methods and applications of value of information in academia and practice.

Authors:  Lotte Steuten; Gijs van de Wetering; Karin Groothuis-Oudshoorn; Valesca Retèl
Journal:  Pharmacoeconomics       Date:  2013-01       Impact factor: 4.981

4.  Prioritizing Additional Data Collection to Reduce Decision Uncertainty in the HIV/AIDS Response in 6 US Cities: A Value of Information Analysis.

Authors:  Xiao Zang; Hawre Jalal; Emanuel Krebs; Ankur Pandya; Haoxuan Zhou; Benjamin Enns; Bohdan Nosyk
Journal:  Value Health       Date:  2020-10-03       Impact factor: 5.725

5.  Comparing methods of data synthesis: re-estimating parameters of an existing probabilistic cost-effectiveness model.

Authors:  Mark Oppe; Maiwenn Al; Maureen Rutten-van Mölken
Journal:  Pharmacoeconomics       Date:  2011-03       Impact factor: 4.981

6.  CDX2 Biomarker Testing and Adjuvant Therapy for Stage II Colon Cancer: An Exploratory Cost-Effectiveness Analysis.

Authors:  Fernando Alarid-Escudero; Deborah Schrag; Karen M Kuntz
Journal:  Value Health       Date:  2021-11-02       Impact factor: 5.725

7.  Cost-effectiveness of direct surgery versus preoperative octreotide therapy for growth-hormone secreting pituitary adenomas.

Authors:  Shaun J Kilty; Myriam G M Hunink; Lisa Caulley; Eline Krijkamp; Mary-Anne Doyle; Kednapa Thavorn; Fahad Alkherayf; Nick Sahlollbey; Selina X Dong; Jason Quinn; Stephanie Johnson-Obaseki; David Schramm
Journal:  Pituitary       Date:  2022-08-27       Impact factor: 3.599

8.  Genetic testing in combination with preventive donepezil treatment for patients with amnestic mild cognitive impairment: an exploratory economic evaluation of personalized medicine.

Authors:  Sandjar Djalalov; Jean Yong; Jaclyn Beca; Sandra Black; Gustavo Saposnik; Zahra Musa; Katherine Siminovitch; Myla Moretti; Jeffrey S Hoch
Journal:  Mol Diagn Ther       Date:  2012-12       Impact factor: 4.074

9.  Evaluation of health research: measuring costs and socioeconomic effects.

Authors:  Kerstin Roback; Koustuv Dalal; Per Carlsson
Journal:  Int J Prev Med       Date:  2011-10

10.  Chapter 10: deciding whether to complement a systematic review of medical tests with decision modeling.

Authors:  Thomas A Trikalinos; Shalini Kulasingam; William F Lawrence
Journal:  J Gen Intern Med       Date:  2012-06       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.